{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:23Z","timestamp":1790155703065,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Enzyme replacement therapy (ERT) with \u03b1-galactosidase A (\u03b1-Gal A) is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease. However, ERT has limitations of a short half-life, requirement for frequent administration, and limited efficacy for patients with renal failure. Therefore, we investigated the efficacy of recombinant adeno-associated virus (rAAV) vector-mediated gene therapy for a Fabry disease mouse model and compared it with that of ERT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A pseudotyped rAAV2\/8 vector encoding \u03b1-Gal A cDNA (rAAV2\/8-hAGA) was prepared and injected into 18-week-old male Fabry mice through the tail vein. The \u03b1-Gal A expression level and globotriaosylceramide (Gb3) levels in the Fabry mice were examined and compared with Fabry mice with ERT. Immunohistochemical and ultrastructural studies were conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Treatment of Fabry mice with rAAV2\/8-hAGA resulted in the clearance of accumulated Gb3 in tissues such as liver, spleen, kidney, heart, and brain with concomitant elevation of \u03b1-Gal A enzyme activity. Enzyme activity was elevated for up to 60 weeks. In addition, expression of the \u03b1-Gal A protein was identified in the presence of rAAV2\/8-hAGA at 6, 12, and 24 weeks after treatment. \u03b1-Gal A activity was significantly higher in the mice treated with rAAV2\/8-hAGA than in Fabry mice that received ERT. Along with higher \u03b1-Gal A activity in the kidney of the Fabry mice treated with gene therapy, immunohistochemical studies showed more \u03b1-Gal A expression in the proximal tubules and glomerulus, and less Gb3 deposition in Fabry mice treated with this gene therapy than in mice given ERT. The \u03b1-gal A gene transfer significantly reduced the accumulation of Gb3 in the tubules and podocytes of the kidney. Electron microscopic analysis of the kidneys of Fabry mice also showed that gene therapy was more effective than ERT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The rAAV2\/8-hAGA mediated \u03b1-Gal A gene therapy provided improved efficiency over ERT in the Fabry disease mouse model. Furthermore, rAAV2\/8-hAGA-mediated expression showed a greater effect in the kidney than ERT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1423-0127-17-26","type":"journal-article","created":{"date-parts":[[2010,4,16]],"date-time":"2010-04-16T18:15:03Z","timestamp":1271441703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Characterization of Fabry mice treated with recombinant adeno-associated virus 2\/8-mediated gene transfer"],"prefix":"10.1186","volume":"17","author":[{"given":"Jin-Ok","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Chul","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,16]]},"reference":[{"key":"140_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency. N Engl J Med. 1967, 276: 1163-1167.","journal-title":"N Engl J Med"},{"key":"140_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1146\/annurev.med.57.110104.115650","volume":"57","author":"RO Brady","year":"2006","unstructured":"Brady RO: Enzyme replacement for lysosomal diseases. Annu Rev Med. 2006, 57: 283-296. 10.1146\/annurev.med.57.110104.115650.","journal-title":"Annu Rev Med"},{"key":"140_CR3","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jpeds.2004.01.051","volume":"144","author":"RJ Desnick","year":"2004","unstructured":"Desnick RJ, Brady RO: Fabry disease in childhood. J Pediatr. 2004, 144: S20-26. 10.1016\/j.jpeds.2004.01.051.","journal-title":"J Pediatr"},{"key":"140_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/ana.410310410","volume":"31","author":"GA DeVeber","year":"1992","unstructured":"DeVeber GA, Schwarting GA, Kolodny EH, Kowall NW: Fabry disease: immune-cytochemical characterization of neuronal involvement. Ann Neurol. 1992, 31: 409-415. 10.1002\/ana.410310410.","journal-title":"Ann Neurol"},{"key":"140_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1073\/pnas.97.1.365","volume":"97","author":"R Schiffmann","year":"2000","unstructured":"Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K: Infusion of \u03b1-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA. 2000, 97: 365-370. 10.1073\/pnas.97.1.365.","journal-title":"Proc Natl Acad Sci USA"},{"key":"140_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ: Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001, 345: 9-16. 10.1056\/NEJM200107053450102.","journal-title":"N Engl J Med"},{"key":"140_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/glycob\/cwg034","volume":"13","author":"K Lee","year":"2003","unstructured":"Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J, Geagan L, Qiu H, Seiger K, Barngrover D, McPherson JM: A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology. 2003, 13: 305-313. 10.1093\/glycob\/cwg034.","journal-title":"Glycobiology"},{"key":"140_CR8","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001, 285: 2743-2749. 10.1001\/jama.285.21.2743.","journal-title":"JAMA"},{"key":"140_CR9","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N: Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007, 18: 1547-1557. 10.1681\/ASN.2006080816.","journal-title":"J Am Soc Nephrol"},{"key":"140_CR10","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1089\/10430349950017293","volume":"10","author":"T Takenaka","year":"1999","unstructured":"Takenaka T, Qin G, Brady RO, Medin JA: Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease. Hum Gene Ther. 1999, 10: 1931-1939. 10.1089\/10430349950017293.","journal-title":"Hum Gene Ther"},{"key":"140_CR11","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1089\/10430349950017671","volume":"10","author":"RJ Ziegler","year":"1999","unstructured":"Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette P, Romanczuk H, Ioannou YA, Zeidner KM, Desnick RJ, Cheng SH: Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum Gene Ther. 1999, 10: 1667-1682. 10.1089\/10430349950017671.","journal-title":"Hum Gene Ther"},{"key":"140_CR12","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1073\/pnas.051634498","volume":"98","author":"SC Jung","year":"2001","unstructured":"Jung SC, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P: Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA. 2001, 98: 2676-2681. 10.1073\/pnas.051634498.","journal-title":"Proc Natl Acad Sci USA"},{"key":"140_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/sj.mt.6300066","volume":"15","author":"RJ Ziegler","year":"2007","unstructured":"Ziegler RJ, Cherry M, Barbon CM, Li C, Bercury SD, Armentano D, Desnick RJ, Cheng SH: Correction of the biochemical and functional deficits in Fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. Mol Ther. 2007, 15: 492-500. 10.1038\/sj.mt.6300066.","journal-title":"Mol Ther"},{"key":"140_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ymthe.2005.08.017","volume":"13","author":"G Gao","year":"2006","unstructured":"Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L, Figueredo J, Lock M, Wilson JM: Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther. 2006, 13: 77-87. 10.1016\/j.ymthe.2005.08.017.","journal-title":"Mol Ther"},{"key":"140_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB: Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine. 2002, 81: 122-138. 10.1097\/00005792-200203000-00003.","journal-title":"Medicine"},{"key":"140_CR16","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","volume":"94","author":"T Ohshima","year":"1997","unstructured":"Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, Kulkarni AB: \u03b1-Galactosidase A deficient mice: A model of Fabry disease. Proc Natl Acad Sci USA. 1997, 94: 2540-2544. 10.1073\/pnas.94.6.2540.","journal-title":"Proc Natl Acad Sci USA"},{"key":"140_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1086\/316953","volume":"68","author":"YA Ioannou","year":"2001","unstructured":"Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ: Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet. 2001, 68: 14-25. 10.1086\/316953.","journal-title":"Am J Hum Genet"},{"key":"140_CR18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0021-9258(17)38286-8","volume":"253","author":"JW Kusiak","year":"1978","unstructured":"Kusiak JW, Quirk JM, Brady RO: Purification and properties of the two major isozymes of \u03b1-galactosidase from human placenta. J Biol Chem. 1978, 253: 184-190.","journal-title":"J Biol Chem"},{"key":"140_CR19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0022-2275(20)39314-7","volume":"6","author":"HG Rose","year":"1965","unstructured":"Rose HG, Oklander M: Improved procedure for the extraction of lipids from human erythrocytes. J Lipid Res. 1965, 6: 428-431.","journal-title":"J Lipid Res"},{"key":"140_CR20","first-page":"1","volume":"42","author":"SK Shahi","year":"1999","unstructured":"Shahi SK, Ranga S, Khurana SK, Talib VH: Free\/total prostate specific antigen ratio: a new hope. Indian J Pathol Microbiol. 1999, 42: 1-2.","journal-title":"Indian J Pathol Microbiol"},{"key":"140_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1128\/JVI.79.1.214-224.2005","volume":"79","author":"H Nakai","year":"2005","unstructured":"Nakai H, Fuess S, Storm TA, Muramatsu S, Nara Y, Kay MA: Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol. 2005, 79: 214-224. 10.1128\/JVI.79.1.214-224.2005.","journal-title":"J Virol"},{"key":"140_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ajkd.2005.03.016","volume":"46","author":"A Pisani","year":"2005","unstructured":"Pisani A, Spinelli L, Sabbatini M, Andreucci MV, Procaccini D, Abbaterusso C, Pasquali S, Savoldi S, Comotti C, Cianciaruso B: Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis. 2005, 46: 120-127. 10.1053\/j.ajkd.2005.03.016.","journal-title":"Am J Kidney Dis"},{"key":"140_CR23","doi-asserted-by":"crossref","unstructured":"Alroy J, Sabnis S, Kopp JB: Renal pathology in Fabry disease. J Am Soc Nephrol. 2002, S134-138. Suppl 2","DOI":"10.1097\/01.ASN.0000016684.07368.75"},{"key":"140_CR24","doi-asserted-by":"publisher","first-page":"9451","DOI":"10.1128\/JVI.74.20.9451-9463.2000","volume":"74","author":"H Nakai","year":"2000","unstructured":"Nakai H, Storm TA, Kay MA: Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol. 2000, 74: 9451-9463. 10.1128\/JVI.74.20.9451-9463.2000.","journal-title":"J Virol"},{"key":"140_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","volume":"21","author":"S Daya","year":"2008","unstructured":"Daya S, Berns KI: Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008, 21: 583-593. 10.1128\/CMR.00008-08.","journal-title":"Clin Microbiol Rev"},{"key":"140_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","volume":"9","author":"RJ Ziegler","year":"2004","unstructured":"Ziegler RJ, Lonning SM, Armentano D, Li C, Souza DW, Cherry M, Ford C, Barbon CM, Desnick RJ, Gao G, Wilson JM, Peluso R, Godwin S, Carter BJ, Gregory RJ, Wadsworth SC, Cheng SH: AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther. 2004, 9: 231-240. 10.1016\/j.ymthe.2003.11.015.","journal-title":"Mol Ther"},{"key":"140_CR27","first-page":"353","volume":"48","author":"M Shimmoto","year":"1997","unstructured":"Shimmoto M, Kase R, Itoh K, Utsumi K, Ishii S, Taya C, Yonekawa H, Sakuraba H: Generation and characterization of transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution causing a variant form of Fabry disease. Vision Res. 1997, 48: 353-359.","journal-title":"Vision Res"},{"key":"140_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0925-4439(98)00012-X","volume":"1406","author":"R Kase","year":"1998","unstructured":"Kase R, Shimmoto M, Itoh K, Utsumi K, Kotani M, Taya C, Yonekawa H, Sakuraba H: Immunohistochemical characterization of transgenic mice highly expressing human lysosomal alpha-galactosidase. Biochim Biophys Acta. 1998, 1406: 260-266.","journal-title":"Biochim Biophys Acta"},{"key":"140_CR29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1681\/ASN.2006080822","volume":"18","author":"EI Christensen","year":"2007","unstructured":"Christensen EI, Zhou Q, S\u00f8rensen SS, Rasmussen AK, Jacobsen C, Feldt-Rasmussen U, Nielsen R: Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J Am Soc Nephrol. 2007, 18: 698-706. 10.1681\/ASN.2006080822.","journal-title":"J Am Soc Nephrol"},{"key":"140_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev.bi.60.070191.001353","volume":"60","author":"EF Neufeld","year":"1991","unstructured":"Neufeld EF: Lysosomal storage diseases. Annu Rev Biochem. 1991, 60: 257-280. 10.1146\/annurev.bi.60.070191.001353.","journal-title":"Annu Rev Biochem"},{"key":"140_CR31","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","volume":"13","author":"M Branton","year":"2002","unstructured":"Branton M, Schiffmann R, Kopp JB: Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol. 2002, 13: S139-143.","journal-title":"J Am Soc Nephrol"},{"key":"140_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/ncpneph0806","volume":"4","author":"A Ortiz","year":"2008","unstructured":"Ortiz A, Oliveira JP, Wanner C: Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol. 2008, 4: 327-336. 10.1038\/ncpneph0806.","journal-title":"Nat Clin Pract Nephrol"},{"key":"140_CR33","first-page":"823","volume":"2","author":"FC Fervenza","year":"2008","unstructured":"Fervenza FC, Torra R, Warnock DG: Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics. 2008, 2: 823-843.","journal-title":"Biologics"},{"key":"140_CR34","first-page":"71","volume":"47","author":"O Kawamura","year":"1997","unstructured":"Kawamura O, Sakuraba H, Itoh K, Suzuki Y, Doi M, Kuwabara H, Oshima S, Abe S, Warabi H, Yoshizawa N: Subclinical Fabry's disease occurring in the context of IgA nephropathy. Clin Nephrol. 1997, 47: 71-75.","journal-title":"Clin Nephrol"},{"key":"140_CR35","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1681\/ASN.2006121400","volume":"18","author":"H Tahir","year":"2007","unstructured":"Tahir H, Jackson LL, Warnock DG: Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol. 2007, 18: 2609-2617. 10.1681\/ASN.2006121400.","journal-title":"J Am Soc Nephrol"},{"key":"140_CR36","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1089\/hum.2009.094","volume":"20","author":"N Cl\u00e9ment","year":"2009","unstructured":"Cl\u00e9ment N, Knop DR, Byrne BJ: Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum Gene Ther. 2009, 20: 796-806. 10.1089\/hum.2009.094.","journal-title":"Hum Gene Ther"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1423-0127-17-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T03:59:05Z","timestamp":1630468745000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/1423-0127-17-26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,16]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1186\/1423-0127-17-26","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,16]]},"assertion":[{"value":"16 February 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"26"}}